Onyx Stock Hits New 52-Week High (ONXX)

NEW YORK ( TheStreet) -- Onyx Pharmaceuticals (Nasdaq: ONXX) hit a new 52-week high Wednesday as it is currently trading at $46.26, above its previous 52-week high of $46.07 with two million shares traded as of 10:50 a.m. ET. Average volume has been 850,700 shares over the past 30 days.

Onyx has a market cap of $2.79 billion and is part of the health care sector and drugs industry. Shares are down 1.2% year to date as of the close of trading on Tuesday.

Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies that target the molecular mechanisms causing cancer the United States, Canada, and Europe. The company has a P/E ratio of 36.5, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Onyx as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good. You can view the full Onyx Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

If you liked this article you might like

Biotech Stock Mailbag: Rebounding From Hillary's Drug Tweet; Global Blood Weighs on Bluebird

The Street Can't Help but Love Amgen

Biotech Stock Bubble Talk Deflated By Cost-Conscious Buyers

Trade-Ideas: Onyx Pharmaceuticals (ONXX) Is Today's "Water-Logged And Getting Wetter" Stock

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan